The Microbiome and Prostate Cancer Risk
Purpose of the Review
There is an abundance of evidence that the human microbiome plays an important and nuanced role in controlling human metabolism, immunity, and cancer. Herein we aim to review the most current research looking at prostate cancer and its link with the gut and genitourinary microbiome.
Recent Findings Summary
There is now a host of evidence for a unique genitourinary (GU) microbiome. The prostate microbiota, to include viral, bacterial, fungal, and parasitic contributions, as assessed from formalin-fixed tissue is described nicely in the study by Banerjee et al. Further hierarchical analysis by this group found a unique microbiome signature for higher Gleason score cancers and validation PCR studies noted a marked number of viral genomic insertions into host DNA. Shretha et al. also recently established unique GU microbiomes in patients with prostate cancer or benign prostate pathology based on urine samples. The gut microbiome likely also has an indirect but significant role in prostate cancer development and treatment. Liss et al. and Golombos et al. found significant associations between specific gut microbiota and prostate cancer. Interestingly, the balance of inflammatory and anti-inflammatory bacterial lipopolysaccharides, production of bile salts, and metabolism of dietary fiber to short chain fatty acids all likely play important roles in creating systemic pro- or anti-carcinogenic states. In terms of prostate cancer treatment effects, Sfanos et al. noted a unique microbial signature in patients undergoing oral androgen deprivation therapy (ADT) as compared with prostate cancer patients not on ADT. Patients undergoing ADT also had enrichment of bacterial metabolic pathways promoting androgen synthesis. Together, these studies have identified a unique GU microbiome and linked both the GU microbiome and unique gut microbial signatures with prostate cancer and prostate cancer treatments. Whether this information can be used in cancer prevention, treatment, or diagnosis are areas of ongoing and active research.
KeywordsProstate cancer Microbiota Gut microbiome Genitourinary microbiome
Compliance with Ethical Standards
Conflict of Interest
Karen M. Wheeler and Michael A. Liss each declare no potential conflicts of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 7.Chen C, Huang X, Fang S, Yang H, He M, Zhao Y, et al. Contribution of host genetics to the variation of microbial composition of cecum lumen and feces in pigs. Front Microbiol. 2018;9:2626–6.Google Scholar
- 9.Konkol Y, Keskitalo A, Vuorikoski H, Pietila S, Elo LL, Munukka E, et al. Chronic nonbacterial prostate inflammation in a rat model is associated with changes of gut microbiota that can be modified with a galactoglucomannan-rich hemicellulose extract in the diet. BJU Int. 2019;123:899–908.CrossRefGoogle Scholar
- 22.Bajic P, Van Kuiken ME, Burge BK, Kirshenbaum EJ, Joyce CJ, Wolfe AJ, et al. Male bladder microbiome relates to lower urinary tract symptoms. Eur Urol Focus. 2018.Google Scholar
- 24.Feng Y, Ramnarine VR, Bell R, Volik S, Davicioni E, Hayes VM, et al. Metagenomic and metatranscriptomic analysis of human prostate microbiota from patients with prostate cancer. BMC Genomics. 2019;20:146–019-5457-z.Google Scholar
- 25.•• Banerjee S, Robertson ES, Alwine JC, Tian T, Wei Z, Feldman MD et al Microbiome signatures in prostate cancer. 2019. This article is important because it addresses the microbiome of the microbiome in prostate cancer microenvironment. Google Scholar
- 34.Martinez-Fierro M, Leach RJ, Gomez-Guerra L, Garza-Guajardo R, Johnson-Pais T, Beuten J, et al. Identification of viral infections in the prostate and evaluation of their association with cancer. BMC Cancer. 2010;10:326–6.Google Scholar
- 48.d’Hennezel E, Abubucker S, Murphy LO, Cullen TW. Total lipopolysaccharide from the human gut microbiome silences toll-like receptor signaling. mSystems. 2017;2. https://doi.org/10.1128/mSystems.00046-17 eCollection.
- 50.EMM Quigley. Leaky gut - concept or clinical entity? Curr Opin Gastroenterol. 2016; 32.Google Scholar
- 60.• Golombos DM, Ayangbesan A, O’Malley P, Lewicki P, Barlow L, Barbieri CE, et al. The role of gut microbiome in the pathogenesis of prostate cancer: a prospective, pilot study. Urology. 2018;111:122–8. This article is of importance because it identifies the enrichment of bacteroidetes in the feces of prostate cancer patients compared to men with BPH. CrossRefGoogle Scholar
- 74.Newton RU, Christophersen CT, Fairman CM, Hart NH, Taaffe DR, Broadhurst D, et al. Does exercise impact gut microbiota composition in men receiving androgen deprivation therapy for prostate cancer? A single-blinded, two-armed, randomised controlled trial. BMJ Open. 2019;9:e024872.CrossRefGoogle Scholar
- 76.Liu Y, Wu X, Jiang H. High dietary fat intake lowers serum equol concentration and promotes prostate carcinogenesis in a transgenic mouse prostate model. Nutr Metab (Lond). 2019;16:24–019-0351-x eCollection 2019.Google Scholar
- 77.• Sfanos KS, Markowski MC, Peiffer LB, Ernst SE, White JR, Pienta KJ, et al. Compositional differences in gastrointestinal microbiota in prostate cancer patients treated with androgen axis-targeted therapies. Prostate Cancer Prostatic Dis. 2018;21:539–48. This article address the microbiome in advanced prostate cancer in men on androgen deprivation. CrossRefGoogle Scholar